CD209(DC-SIGN) Antibody

Catalog Number:

21600

Amount:

100μg

Price:

$319

Swiss-Prot No:

Swiss-Prot: Q9NNX6
NCBI Protein: NP_066978.1

Form of Antibody:

Supplied at 1.0mg/mL in phosphate buffered saline (without Mg2+ and Ca2+), pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol.

Storage/Stability:

Immunogen:

Peptide sequence around aa.389~393( E-Q-F-L-S )derived from Human CD209 (DC-SIGN).

Purification:

Antibodies were produced by immunizing rabbits with synthetic peptide and KLH conjugates. Antibodies were purified by affinity-chromatography using epitope-specific peptide.

Specificity/Sensitivity:

The antibody detects endogenous level of total CD209 (DC-SIGN) protein.

Applications:

WB

Background:

Pathogen-recognition receptor expressed on the surface of immature dendritic cells (DCs) and involved in initiation of primary immune response. Thought to mediate the endocytosis of pathogens which are subsequently degraded in lysosomal compartments. The receptor returns to the cell membrane surface and the pathogen-derived antigens are presented to resting T-cells via MHC class II proteins to initiate the adaptive immune response. Probably recognizes in a calcium-dependent manner high mannose N-linked oligosaccharides in a variety of pathogen antigens, including HIV-1 gp120, HIV-2 gp120, SIV gp120, ebolavirus glycoproteins, cytomegalovirus gB, HCV E2, dengue virus gE, Leishmania pifanoi LPG, Lewis-x antigen in Helicobacter pylori LPS, mannose in Klebsiella pneumonae LPS, di-mannose and tri-mannose in Mycobacterium tuberculosis ManLAM and Lewis-x antigen in Schistosoma mansoni SEA. On DCs it is a high affinity receptor for ICAM2 and ICAM3 by binding to mannose-like carbohydrates. May act as a DC rolling receptor that mediates transendothelial migration of DC presursors from blood to tissues by binding endothelial ICAM2. Seems to regulate DC-induced T-cell proliferation by binding to ICAM3 on T-cells in the immunological synapse formed between DC and T-cells.

Geijtenbeek T.B.H., Kwon D.S., Torensma R., van Vliet S.J. Cell 100:587-597(2000)
Geijtenbeek T.B.H., Krooshoop D.J., Bleijs D.A., van Vliet S.J. Nat. Immunol. 1:353-357(2000)
Engering A., Geijtenbeek T.B.H., van Vliet S.J., van Kooyk Y.J. Immunol. 168:2118-2126(2002)

References:

appl_detail:

Predicted MW: 46kd
Western blotting: 1:500~1:1000

Datasheet PDF